In The Know: RA treatment algorithm — Mapping the future of the rheumatoid arthritis treatment landscape

Research with a dozen world-renowned rheumatologists has shed light on how emerging rheumatoid arthritis (RA) therapies might shape the future competitive landscape.  

In Figure 1, the views of 12 RA key opinion leaders (KOLs), given in a series of in-depth interviews about existing and potential treatment options for RA patients (see Table 1), have been plotted to map how the RA treatment algorithm could play out.

Figure 1: Current and future treatment of RA

Source: FirstWord, Rheumatoid Arthritis: KOL Insight March 2018

Table 1: Products covered with KOLs in this research

Brand Name Generic Name Company
Humira adalimumab AbbVie
Enbrel etanercept Amgen/Pfizer
Remicade infliximab Janssen Biotech/Merck & Co.
Cimzia certolizumab UCB
Simponi golimumab Janssen Biotech/Merck & Co.
Actemra/RoActemra tocilizumab Roche
Orencia abatacept Bristol-Myers Squibb
Rituxan/MabThera rituximab Biogen/Roche
Xeljanz tofacitinib Pfizer
Olumiant baricitinib Incyte/Eli Lilly
Kevzara sarilumab Sanofi/Regeneron
- olokizumab R-Pharm/UCB
- upadacitinib (ABT 494) AbbVie
- filgotinib (GLPG 0634) Galapagos/Gilead Sciences
- piclidenoson (CF 101) Can-Fite

Click here to discuss this research with a FirstWord consultant.

FirstWord conducts similar research in nearly 30 evolving disease areas. Contact us to learn more.

To read more Sponsored Story articles, click here.

Reference Articles